Thursday, September 22, 2011 7:36:27 PM
FYI- Klon was invited to the SEC to talk about Cortelazzi, Ollu and De Montigny yesterday:
Klonopin2mg2000
Share
Tuesday, September 13, 2011 8:54:01 PM
Re: CHUNKY44 post# 330110
Post # of 330282
you are correct...and Andrea Cortellazzi got what he had coming too. let that be a reminder, i don't like to lose and i don't like being lied too. especially don't like people trying to steal or defraud me out of my hard earned money.
ask earnestDD, he'll tell you i finally caught on to the "business".
and if it makes you feel better, yes...i lost a great deal of money.
but he's paying for it.
next up! a visit to the SEC on the 21st, Chicago
take care CHUNKY
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67066695
Klon will have much to say to receptive ears....
Recent MRES News
- M2Bio Sciences Appoints Adrian J. Maizey, Accomplished CEO and Financial Expert, to Advisory Board • InvestorsHub NewsWire • 07/19/2023 01:18:56 PM
- M2Bio Sciences Unveils an Exciting Line of Purple, White, and Green Teas from Kenya, Offering Extraordinary Health and Medicinal Benefits • InvestorsHub NewsWire • 07/14/2023 12:52:00 PM
- M2Bio Sciences Unveils Explainer Video Showcasing Groundbreaking NFTs and Altcoins for Drug Discovery, Revolutionizing Investment Access • InvestorsHub NewsWire • 07/06/2023 01:38:23 PM
- Institute of Biomedical Research Announces Application for Name Change and New Ticker Symbol in Anticipation of Future M&A Activities and Senior Listing • InvestorsHub NewsWire • 07/05/2023 02:04:17 PM
- M2Bio Sciences Enters into Letter of Intent to Acquire Crypto Exchange JDAX • InvestorsHub NewsWire • 06/26/2023 12:45:19 PM
- M2Bio Sciences Establishes Research Chair at The University of Pretoria for Phytomedicines • InvestorsHub NewsWire • 06/16/2023 12:30:00 PM
- M2Enviro Expands R&D Efforts to Explore Diverse Classes of Mycelium Composite Materials for Commercialization • InvestorsHub NewsWire • 06/14/2023 12:00:00 PM
- Institute of Biomedical Research unveils artificial intelligence (AI) powered initiatives within its CBD product range, psilocybin research, and cardiometabolic health solutions • InvestorsHub NewsWire • 06/07/2023 02:06:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM